Psychostimulant Treatment of Cocaine Dependence
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Synopsis Cocaine dependence continues to be a significant public health problem and no clearly effective pharmacotherapy has yet been identified. Substitution pharmacotherapy is an effective approach for treating opioid and nicotine dependence, and accumulating evidence indicates that stimulant pharmacotherapy for cocaine dependence is a promising strategy. Broadly, stimulant medications that produce behavioral arousal, and medications across several therapeutic classes can be considered psychostimulants. To date, the available evidence is strongest for amphetamine analogs or dopaminergic agents combined with contingency management behavioral interventions as potential psychostimulant treatments for cocaine dependence. Most psychostimulants are controlled substances with inherent risks of misuse and diversion, and their use in patients with active substance use disorders is complex. As stimulant substitution treatment models for cocaine dependence are developed, particular attention to patient risk stratification is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“8%.[56] These data indicate that co-occurring ADHD and cocaine dependence will be routinely encountered in clinical settings.”
BackgroundHasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824 · cited 1×
“Misuse, diversion, and addiction are inherent risks of prescribing controlled substances, and a substantial minority of patients prescribed stimulants will divert their medications to others or misuse their own prescription.[61] An assessment of risk in a specific patient has to be determined at a specific point in ti…”
BackgroundNew Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731 · cited 1×
“Amphetamines cause release of monoamines, in particular dopamine, and also blocks monoamine reuptake.[27] These actions are similar to cocaine (dopamine reuptake blockade), although the half-life of amphetamines, in particular long-acting formulations, [28] are much longer than cocaine.”
BackgroundModafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567 · cited 1×
“Substitution pharmacotherapy, which has been proven effective for opioid [9] and nicotine [10] dependence, is a plausible strategy for treating cocaine dependence.”
BackgroundCamí, J., & Farré, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023160 · Cited by 477
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 2×
“Volkow and Swanson,[60] identified four variables that affected the therapeutic and reinforcing effects of methylphenidate, which included: 1. dose 2. pharmacokinetics 3. individual differences in sensitivity to methylphenidate 4. context Large doses that penetrate the blood brain barrier rapidly are associated with g…”
BackgroundFaraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review
Kollins, S. H., MacDonald, E. K., & Rush, C. R. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00464-6 · Cited by 365
Spencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250 · cited 1×
“Amphetamines[57] and methylphenidate[58] are effective treatments for treating adult ADHD.”
BackgroundSchubiner, H., Downey, K. K., Arfken, C. L., Johanson, C.-E., Schuster, C. R., Lockhart, N., Edwards, A., Donlin, J., & Pihlgren, E. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.10.3.286 · Cited by 249
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243
Modafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235 · cited 2×
“However, the follow-up multi-site trial of 210 participants randomized to placebo, modafinil 200 mg/daily, or modafinil 400 mg daily, showed no advantage of modafinil on the primary outcome measure.[36] Secondary outcomes, including reduction of craving and the maximum number of consecutive non-use days for cocaine, f…”
BackgroundLevin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.07.004 · Cited by 220 · cited 2×
“Levin et al.[42] evaluated methylphenidate in comparison to placebo for the treatment of co-occurring ADHD and cocaine dependence in Psychiatr Clin North Am.”
BackgroundSelf-citationMartinez, D., Carpenter, K. M., Liu, F., Slifstein, M., Broft, A., Friedman, A. C., Kumar, D., Van Heertum, R., Kleber, H. D., & Nunes, E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050748 · Cited by 212
Grabowski, J., Rhoades, H., Stotts, A., Cowan, K., Kopecky, C., Dougherty, A., Moeller, F. G., Hassan, S., & Schmitz, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300392 · Cited by 185 · cited 4×
“Grabowski et al.[29] evaluated dextroamphetamine in two escalating dosing schedules (15 to 30 mg daily and 30 to 60 mg daily) to placebo for the treatment of cocaine dependence in 128 outpatients.”
BackgroundInfluentialA multicenter trial of bupropion for cocaine dependence in methadone-maintained patients
Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., Arndt, I. O., Cornish, J., Ascher, J. A., Li, S.-H., et al. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01198-6 · Cited by 168
Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124 · cited 1×
“[32] reported that in 82 cocaine-dependent outpatients the sustained release preparation of methamphetamine was found to be associated with lower rates of cocaine-positive urine samples and greater reduction in craving than placebo, while the immediate-release formulation of methamphetamine was not superior to placebo…”
BackgroundLevodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform
Schmitz, J. M., Mooney, M. E., Moeller, F. G., Stotts, A. L., Green, C., & Grabowski, J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.004 · Cited by 124
Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Kao, U. H., Wang, P.-C., Bholat, M. A., & Ling, W. (2008) · Journal of Addictive Diseases · doi:10.1300/j069v27n01_02 · Cited by 54 · cited 1×
“Shoptaw et al.[47] compared bupropion to placebo in a double-blind trail of 70 cocaine-dependent outpatients and found no differences between treatment groups.”
Background
Cited by
Excessive cocaine use results from decreased phasic dopamine signaling in the striatum
Willuhn, I., Burgeno, L. M., Groblewski, P. A., & Phillips, P. E. M. (2014) · Nature Neuroscience · doi:10.1038/nn.3694 · Cited by 261
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
Self-citationTardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
Self-citationRisk factors for stimulant use among homeless and unstably housed adult women
Riley, E. D., Shumway, M., Knight, K. R., Guzman, D., Cohen, J., & Weiser, S. D. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.023 · Cited by 46
Karila, L., Leroy, C., Dubol, M., Trichard, C., Mabondo, A., Marill, C., Dubois, A., Bordas, N., Martinot, J.-L., Reynaud, M., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.28 · Cited by 27
Metadata
- Authors
- Mariani, J. J., & Levin, F. R.
- Venue
- Psychiatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 35
- Issue
- 2
- Pages
- 425-439
- ISSN
- 0193-953X (ISSN-L)
- OpenAlex
- W2168620692
- Cited by
- 80
- References
- 24
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.